MHRA acts against clinic advertising Kenalog for hay fever
The MHRA has taken regulatory action against a private clinic for advertising Kenalog as a hay fever treatment. The agency said the drug is not only prescription-only — meaning it cannot be advertised directly to the public — but also holds no UK licence for that indication.
What happened
The MHRA ruled against a private clinic that had promoted Kenalog, the brand name for triamcinolone acetonide, as a treatment for hay fever. The agency's position was unambiguous: Kenalog is a prescription-only medicine (POM), and advertising POMs to the public is prohibited under UK medicines law. On top of that, the agency confirmed Kenalog is not a licensed treatment for hay fever at all, making the promotion unlicensed on two counts.
Triamcinolone acetonide is a corticosteroid injection. It has licensed uses in the UK, but hay fever is not among them. Private clinics offering it for seasonal allergic rhinitis have been a recurring flashpoint, particularly during peak pollen season when demand from patients seeking a single-injection fix tends to rise.
Why it matters
This case is a clean illustration of how medicines advertising law works in practice — and where private providers sometimes push against it.
The rules are set out clearly. You cannot advertise a POM to the public. Full stop. That prohibition exists regardless of whether a medicine is licensed, unlicensed, or used off-label. The MHRA's point about Kenalog not being licensed for hay fever adds another layer: even if a clinician can legally prescribe it off-label in appropriate circumstances, a clinic cannot then run a public-facing advertisement promoting it for that use. Prescribing off-label and advertising off-label are two entirely different things.
For anyone working in or around pharmacy, this distinction matters. Patients frequently come in having seen online adverts — for injections, infusions, supplements, and medicines — that would not pass regulatory scrutiny. Knowing the framework helps you field those conversations accurately. A product being available at a private clinic does not mean it is licensed for what it's being sold for, and advertising that oversteps the law should be reported to the MHRA's Yellow Card scheme or via the MHRA's advertising complaints process.
There's also a patient safety angle. Triamcinolone acetonide is a potent corticosteroid. It carries real risks, including adrenal suppression, effects on blood glucose, and immunosuppression. For a patient with poorly controlled diabetes or an underlying infection, an unrestricted injection marketed as a routine hay fever remedy could cause serious harm. The licensing system and the advertising prohibition both exist partly to make sure patients get proper screening before accessing medicines with that kind of risk profile.
GPhC exam relevance
Medicines law and classification comes up regularly in the GPhC Common Registration Assessment. A few things worth keeping sharp here:
POM advertising rules. The Human Medicines Regulations 2012 prohibit the advertising of prescription-only medicines to the public. This is a firm rule, not a guideline. The MHRA enforces it.
Licensed vs unlicensed use. A medicine can be legally prescribed for an unlicensed indication — that's off-label prescribing, which happens across many specialties. But an unlicensed or off-label use cannot be advertised to patients as if it were a standard treatment option. The prescriber takes on additional responsibility for off-label use; the manufacturer's marketing authorisation does not extend to it.
Kenalog itself. Triamcinolone acetonide is a corticosteroid injection. If you encounter a question about corticosteroid side effects, drug interactions (for example, with antidiabetics or anticoagulants), or the cautions around immunosuppressants, this is the class of drug involved. Know the major adverse effects: adrenal suppression, hyperglycaemia, increased infection risk, osteoporosis with long-term use.
Reporting mechanisms. The MHRA handles complaints about unlawful medicines advertising. Yellow Card handles adverse drug reactions and suspected defective products. Knowing which route applies to which situation is the kind of practical knowledge the assessment tests.
What's next
Watch whether the MHRA follows up with formal enforcement beyond the initial ruling, and whether the clinic amends or removes the advertising in question. The agency has the power to require withdrawal of unlawful promotions and to take further action if a company fails to comply.
More broadly, private clinics offering Kenalog for hay fever have operated in a grey zone for years. This action signals the MHRA is willing to call it out publicly. If you're working in a pharmacy where patients ask about these injections — particularly in spring and early summer — you're in a position to explain both the licensing status and the clinical risks involved.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/regulation/mhra-raps-private-clinic-over-unlicensed-hay-fever-drug-ad-FZGEPKRMONGRJERMRX4H3Q22ZU/